Relation Therapeutics Secures $35M in Seed Funding
Relation Therapeutics, a London, UK-based biotechnology company, has recently secured $35M in Seed funding, bringing the total amount raised to $60M. The funding round was led by DCVC and NVentures, with participation from initial seed lead Magnetic Ventures, existing investors Khosla Ventures, and Abcam founder Jonathan Milner, as well as new investors ARK Invest and Deerfield Management Company. The company plans to use the funds to advance its osteoporosis pipeline towards the clinic and initiate discovery campaigns in new therapeutic areas with high unmet needs.
Relation Therapeutics, led by CEO David Roblin, is focused on discovering and developing transformational medicines using experimental and computational approaches.
The company's Lab-in-the-Loop strategy involves combining single-cell multi-omics directly from patient tissue, functional assays, and machine learning to gain insights into biological processes related to human health and disease. By leveraging its technology and data, Relation is advancing programs targeting bone-related diseases, starting with treatments for osteoporosis.
As part of its research efforts, Relation has established proprietary data resources, including Osteomics, a clinical observational study aimed at creating a comprehensive functional, single-cell bone atlas based on human patient tissue. The company's innovative approach to drug discovery and development holds promise for addressing unmet medical needs and advancing the field of biotechnology. With the recent funding injection, Relation Therapeutics is well-positioned to drive forward its pipeline and make a significant impact in the healthcare industry.
They've invested in Relation Therapeutics
Get to know these Healthtech investors
Click here for a full list of 6,528+ startup investors in the UK